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Abstract
Opiate use has reached epidemic levels in the United States, resulting in 28,647 deaths in
2014 alone. Prenatally, opioids are used for both pain management and to assist with
opiate dependency. The level of risk associated with the use of opiates is much higher for
pregnant women, and women of childbearing age, due to the detrimental effects opiates
have on the developing fetus including, neonatal abstinence syndrome (NAS). Maine is
leading the nation in the number of NAS births with incidence rates of greater than 30 per
1,000 hospital births. Pregnancy prevention is an upstream approach to reduce
unintended pregnancy and prevent NAS. The purpose of this study is to examine
providers’ preconception counseling processes among women of childbearing age who
are prescribed opiates. This descriptive study followed survey research design. The
survey questions were developed based upon the evidence based practice framework,
which involves assessment of patient values, application of best available evidence, and
clinical judgement. Data from this study will provide preliminary information about the
current preconception counseling processes provided to women of childbearing age who
are prescribed opioid analgesics. The long-term goal of this research is to reduce the
number of unintended pregnancies among women who are prescribed opioid
analgesics. This will help to promote public health, and reduce the detrimental effects
that the opiate epidemic has on the community.
Keywords: neonatal abstinence syndrome, contraception, addiction
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Contraceptive Counseling Practices Among Providers Prescribing
Opiates to Women of Childbearing Age in the United States
In the United States, the increasing use of opiates, both prescription medications
and illicit drugs, has reached epidemic proportions. Over the past fifteen years, drug
overdose deaths have nearly tripled, leading to 28,647 deaths in 2014 alone (CDC, 2016
December). The risks associated with opiate use are much higher for pregnant women
due to the detrimental effects on the developing fetus, including NAS. Symptoms of NAS
include: mottled skin, high-pitched crying, hyperactive reflexes, irritability, poor feeding,
rapid breathing, tremors and seizures, and occur because the baby is withdrawing from
the opiates they were exposed to in utero. Forty to eighty percent of neonates who are
exposed to opiates develop NAS, requiring prolonged hospitalization and
pharmacotherapy. (Yazda, Desai, & Brogly, 2015). Amongst women using opiates, 86%
of pregnancies are unintended (Barfield, 2016). It is important to understand that NAS
can result from the use of both illicit drugs and prescription medications. Although the
detrimental effects of this epidemic can be seen across the country, certain states are
more heavily affected than others. On average, one person died every day from a drug
overdose in Maine in 2016. (Maine Attorney General, 2017). The rate of NAS in Maine
is also higher than the national average, with a prevalence rate of than 30 per 1,000
hospital births (Barfield, 2016).
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Literature Review
History of the Issue
Several factors have contributed to this epidemic, including the aggressive
marketing of OxyContin. When Purdue Pharma introduced OxyContin in 1996 it was
aggressively marketed, resulting in sales growth from $48 million in 1996 to almost $1.1
billion in 2000 (Van Zee, 2009). Rural states with unsophisticated primary care,
including Maine, were targeted. From 1995 to 2001, the number of patients in Maine
being treated for opioid abuse increased by 460% (Van Zee, 2009). Another factor that
contributed to the over prescribing of opiates was the emergence of “pain as the 5th vital
sign”. In 1996, the APS introduced this in order to improve pain assessment and
management (National Pharmaceutical Council, 2006). This initiative emphasized that
the pain assessment was an important aspect of a patient assessment, and that physicians
need to act when a patient reports pain. By 2000, the rate of prescribing OxyContin in
Maine was 5 or 6 times higher than the national average, which was one of the highest in
the country (Van Zee, 2009).
Current evidence on prescribing opiates to women of childbearing age
There are two main uses of prescription opioids in pregnancy: pain management
and opioid dependency treatment. Pain is commonly reported in pregnancy, with
prevalence rates of low back and pelvic pain between 68-72%. Both opioid analgesics
and non-steroidal anti-inflammatory drugs (NSAIDs) are used as pharmacological
treatments for acute pain. However, guidelines published from the APS recommend
minimal, or no use, of opioids during pregnancy. The Food and Drug Administration
(FDA) classifies these drugs as Pregnancy Category C, which indicates evidence of
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potential harm to the fetus. Despite documented evidence of adverse effects on fetal
development, there are consistency high documented rates of prenatal use; pregnant
women from 47 states with Medicaid insurance reported that 21.6% of women filled at
least one opioid prescription during their pregnancy (Yazda, Desai, & Brogly, 2015).
Addiction is classified by the four “C” s: impaired control over drug use,
compulsive use, continued use despite harm, and craving (Seikel, 2012). The use of
injection drugs, such as heroin, during pregnancy is associated with poor nutrition and
anemia, high risk of infectious diseases such as HIV and hepatitis, inadequate prenatal
care, and expose the patient to a significant risk of overdose (Newman, 2017). In 2014,
the World Health Organization (WHO) published guidelines for the identification and
management of substance use and substance use disorders in pregnancy. These were
developed primarily as a tool for health care providers who manage women from
conception to birth, during the postnatal periods, and their infants. These evidence-based
recommendations allow health care providers to apply scientific principles when
identifying and managing substance use disorders in pregnant women. There are five
overarching principles of the guideline: prioritizing prevention, ensuring access to
prevention and treatment services, respecting patient autonomy, providing comprehensive
care, and safeguarding against discrimination and stigmatization (WHO, 2014). Although
this guideline addresses the importance of ensuring access to resources, as of 2010 only
19 U.S. states had drug treatment programs for pregnant women and only 9 gave priority
access to pregnant women (Patrick, et al., 2012).
Methadone maintenance therapy (MMT) has been used in the United States since
the 1960’s and is now considered to be the standard of treatment for opioid dependency
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during pregnancy (Yazda, Desai, & Brogly, 2015). The goals of pharmacotherapy
include: prevention or reduction of withdrawal symptoms and craving, prevention of
relapse to use of illicit drugs, restoration of physiological function disrupted by drug use,
and a blockade of the euphoric effects of illicit self-administered opiates (Seikel, 2012).
Benefits of MMT include improved prenatal care adherence, reduced fetal death rates,
and higher infant birth rates compared to illicit drug use alone. Although MMT has been
proven to be the gold standard of treatment, only 37% of pregnant women reporting
opioid abuse at admission to a substance treatment center received this therapy (Yazda,
Desai, & Brogly, 2015). There are many significant obstacles to implementing
methadone treatment, including the stigma associated with pharmacological treatment of
and misconceptions regarding the nature of addiction.
Current evidence on contraception and counseling
In 2014, the CDC published recommendations for providing quality family
planning services. One of the recommendations states that “providers should use a tiered
approach to presenting a broad range of contraceptive methods (including [LARC] such
as intrauterine devices and contraceptive implants), in which the most effective methods
are presented before less effective methods,” (NGC, 2014, page 6). LARC devices have
the ability to prevent unintended pregnancy because of the ease of use, safety, and
efficacy associated with their use. There are several different types of LARC devices
including a copper IUD, a hormonal IUD, and an implant. The hormonal IUD releases
progestin, and has been approved for use for three to five years. The copper IUD does not
contain hormones and can remain in the body for up to ten years. The implant is a
flexible rod which releases progestin into the body, and once inserted into the upper arm,

4

can remain for up to three years. During the first year of typical use fewer than 1 in 100
women using an IUD or an implant will become pregnant (ACOG, 2016). This is the
same efficacy rate as sterilization, but these options are completely reversible. An
assessment of the 2006-2010 National Survey of Family Growth data was conducted and
found that 13% of postpartum women using short-acting hormonal contraception had a
pregnancy within 18 months compared to 0.5% of LARC users (Turok, Gawron, &
Lawson, 2016). There are many other benefits to LARC including the fact that it does not
depend on patient compliance to function properly. Unlike other birth control options,
once it is in place the patient does not have to do anything further to prevent pregnancy.
Although LARCs are currently the most effective form of contraception, there is
opposition to their use. There is a misconception that having an IUD increases the risk for
developing upper genital tract infections. However, this is an outdated belief which is not
supported by evidence and should not be considered a barrier to utilization (Turok,
Gawron, & Lawson, 2016). There has also been concern regarding the safety of LARC
use in pediatric patients. However, a recommendation in the 2014 NGC guidelines states
that, “education about contraceptive methods should include an explanation that LARC is
safe and effective for nulliparous women, including adolescents,” (NGC, 2014, page 9).
Both the AAP (AAP, 2014) and the ACOG (ACOG, 2012) support LARC methods as
first-line choices for adolescents, and recommend LARC without restriction for
nulliparous women. There are two important concepts regarding LARC use in clinical
practice: reducing cost barriers to IUDs and implants, and improving patient counseling
on the superior efficacy and satisfaction associated with these devices (Turok, et al.,
2016).
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Assumptions/biases surrounding substance use during pregnancy
From 2000 to 20009, the number of delivering mothers using or dependent on
opioids rose nearly five-fold, and annual rates of NAS diagnosis increased almost 3-fold
(Patrick, et al., 2012). There have been adequate and extensive studies into the effects of
opiate use during pregnancy in order to gain a better understanding of the problem and
initiate change. There are many factors associated with unplanned pregnancy and
increased risk factors when substance use is involved. Women using opiates are reported
to begin antenatal care late, tend to have underlying medical conditions, and a higher
incidence of obstetric complications (Harding, 2003). There is an inaccurate perception
of risk of pregnancy documented amongst opiate users. Opiate use can cause amenorrhea,
a lack of a menstrual period, which is one reason why women using opiates may believe
they cannot become pregnant (Harding, 2003). Due to this inaccurate perception, there is
a high percentage of sexually active women prescribed methadone and other opiates who
report using no contraception or less reliable methods. In order to develop a personalized
plan of care, health care providers need to assess each woman's perceived pregnancy risk
and desire for future pregnancies, along with including a discussion about contraception
methods (Harding, 2003).
For pregnant women, there is a lot of fear and stigma surrounding addiction
treatment. There are four factors that contribute to the stigma surrounding addiction and
treatment (Olsen & Sharfstein, 2014). First, there is a misunderstanding that addiction is
not a medical illness, but instead a moral weakness or willful choice. However, the NIDA
classifies addiction as a chronic disease, similar to other chronic diseases such as type 2
diabetes, cancer, and cardiovascular disease (NIDA, 2016). The separation of addiction
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treatment from the rest of health care has also contributed to this stigma. This separation
means that physicians who are treating these patients aren’t necessarily considering other
substance abuse disorders, mental health conditions, and their overall physical health
(Olsen & Sharfstein, 2014). The language used to discuss addiction mirrors and
perpetuates this stigma, for example, urine test results are often called “clean” or “dirty,”
rather than “positive” or “negative” (Olsen & Sharfstein, 2014). The criminal justice
system’s treatment of addiction often fails to defer to medical judgement. For example,
when incarcerated, people relying on methadone or buprenorphine replacement therapy
are not always allowed to continue their treatment. It is estimated that 15% of people
entering America’s prison system each year are addicted to heroin, with many of those
enrolled in methadone treatment at the time of their arrest (Mitchell, et al.,
2010). Although this highlights a need for safe and effective treatment, or continuation
of treatment for those enrolled, the majority of U.S. prisons and jails reported that they do
not provide any medications for opioid detoxification (Mitchell, et al., 2010).
The stigma surrounding addiction is a barrier to care, because if women are too
afraid to advocate for themselves they will not receive the resources they need. Seventy
three percent of women reported that during their pregnancies they were afraid of testing
positive for substances at prenatal visits or delivery, losing custody of their newborns,
and experiencing criminal justice consequences (Stone, 2015). This fear is one of the
reasons why many women using opiates report receiving late or inadequate antenatal
care, which is linked to many poor health outcomes for the fetus. A cohort study was
conducted using data from the Center for Disease Control and Prevention’s (CDC, 2016)
Linked Birth-Infant Death and Fetal Death data on all deliveries in the United States
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between 1995 and 2002. Results from this study show that the risks of prematurity,
stillbirth, early and late neonatal decease, and infant death increased linearly with
decreasing care (Patridge, Balayla, Holcroft, & Abenhaim, 2012).
State Responses to the Issue
States vary in their approach to substance exposure in pregnancy. Eighteen states
consider substance abuse during pregnancy to be child abuse. Tennessee is the only state
that allows for assault charges to be filed against a pregnant woman who uses substances
(Guttmacher Institute, 2014). However, both the AMA (AMA, 1990) and ACOG
(ACOG, 2005) both oppose legislation criminalizing maternal drug addiction, as it leads
to reduced prenatal care. A report from the AMA states, “pregnant women will be likely
to avoid seeking prenatal or open medical care for fear that their physician's knowledge
of substance abuse or other potentially harmful behavior could result in a jail sentence
rather than proper medical treatment” (AMA, 1990). In many states, including Maine,
pregnant women have priority access to substance abuse treatment programs (Guttmacher
Institute, 2014). Although it is important that pregnant women have access to these
services, a concern with giving them priority is that women will become pregnant to
avoid the long wait lists at clinics.
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Theoretical Framework
The questions in the survey are based upon the EBP framework, which includes
best available research, patient values, and clinical judgement. The purpose of this
framework is to move from a health care delivery system based on tradition, intuition and
authority, to one that is guided and justified by the best available evidence (Leech, 2006).
Purpose
This descriptive study aimed to understand current preconception counseling
practices among providers who prescribe opiates to women of childbearing age.
Method
Participant Population
Providers at primary care and pediatric institutions within Penobscot Community
Health Care and Centers for Family Medicine in Penobscot County, Maine were targeted
because primary care providers account for about half of opioid pain relievers dispensed
and care for women (Daubresse et al., 2013).
Measurement
The questions aimed to assess provider’s application of current evidence about
contraception and counseling, the provider’s assessment of patient values, and provider’s
clinical judgement. Each question addressed different components of the EBP
framework.
I.

Provider’s application of current evidence about contraception and counseling
i.

When prescribing opiates to a woman of childbearing age, how likely are
you to recommend contraception?

9

ii.

When discussing contraception, how likely are you to recommend long
acting reversible contraception (LARC)?

iii.

When discussing LARC, how likely are you to recommend this method to
adolescents and nulliparous women?

II.

Provider’s assessment of patient values
i.

Please rate the degree to which you agree or disagree with the following
statement: “Providing patients with educational materials relating to the
effects of opiates on pregnancy and recommending LARC would decrease
the number of substance dependent babies born in Maine”

ii.

Please rate the degree to which you agree or disagree with the following
statement: “Providing women with education about the effects of opiates
on pregnancy will influence the patient’s decision to take them.”

III.

Provider’s clinical judgement
i.

When prescribing opiates to a woman of childbearing age, how likely are
you to provide information about the risks of preconception, antenatal, and
postnatal use of opiates?

ii.

What do you think is the most significant barrier to LARC use?

Procedure
The practice director at each location was contacted via e-mail to determine their
willingness to participate. The survey was sent electronically via Qualtrics survey
research software to each practice director, who then distributed it amongst the providers
of their organization. The responses to the survey remained anonymous. Data was stored
into a spreadsheet within Qualtrics on the University of Maine Server system with strong
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privacy controls. Resulting data was accessible only to the research team. All data was
deleted after completion of the study.
Results
Of the 29 providers who participated in the survey, 16 were physicians, 7 were
resident physicians, and 6 were nurse practitioners. Twenty-one of the participants were
female, and 8 were male. The participants ranged in age from 25 to 65+. When
prescribing opiates to women of child-bearing age, 37.93% of providers responded as
extremely likely to provide education about the risks and benefits of their use, while only
6.90% were extremely unlikely (Table 1). Providers were much more likely to provide
contraception counseling, with 51.72% of providers responding as extremely likely
(Table 2). Although the majority of providers are discussing LARC (Table 3), the most
significant barrier to their use is patient understanding of safety and efficacy (Table 7).
Results of the study show that although 41.38% of providers strongly agree that
providing educational materials will decrease the rate of NAS (Table 5), only 24% of
providers agree that providing improved education will influence the patient’s decision to
use opiates (Table 6).
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Conclusion
Maine is being heavily impacted by the effects of the opiate epidemic, especially
in regards to the prevalence of NAS. This can occur as the result of both illicit drugs and
prescription medications, which drives the need for further public education. When
prescribed opiates, women of child bearing age need to be informed of the risks related to
their use, along with the benefits of contraception. Contraception counseling can be
improved using tools developed by ACOG, which specifically address LARC. LARC is
the most effective form of contraception, which requires no patient compliance and poses
no safety risks. When providing patient education, health care providers need to
determine each patient’s level of health literacy to determine which learning style would
be most effective. Improving contraception counseling will help to reduce the rate of
unintended pregnancies amongst women taking opiates and decrease the number of
babies born with NAS.
Nursing Implications
The results of this study highlight the need for improved patient education on
LARCs. Fifty one percent of providers stated the most significant barrier to use was
patient understanding of safety and efficacy (Table 7). This is an important nursing
intervention, as providing patient education is one of the most important roles of the
nurse. Health literacy is defined as, “the degree to which individuals can obtain, process,
and understand the basic health information and services they need to make appropriate
health decisions” (Berkman, et al., 2011). Only 12% of adults in the United States have
proficient health literacy, and over a third of adults would have difficulty with common
health tasks, such as following directions on a prescription drug label (DHHS, 2008).
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Health literacy is lowest among those with lower education, racial and ethnic minorities,
the uninsured and publicly insured, and the elderly (Berkman, et al., 2011). Before
performing patient teaching, each patient's level of health literacy needs to be assessed to
determine barriers to learning. Incorporating the use of educational materials such as
brochures and handouts is one way to improve patient teaching. The American Congress
of Obstetricians and Gynecologists (ACOG) website has several different patient
resources that providers can utilize. ACOG has specifically developed a LARC program
which has a variety of resources including clinical guidance and educational materials for
patients. The purpose of this program is to help reduce unintended pregnancy by
providing improved information and resources on LARC. (ACOG LARC Program,
2017).
Although improving education tools and resources will increase the patient’s
understanding of the risks, it doesn’t necessarily mean it will influence the patient’s
decision. The American Nurses Association (ANA, 2015) has published ethical principles
of nursing, which include autonomy and beneficence amongst others. Autonomy is
defined as the, “agreement to respect another's right to self-determine a course of action,”
while beneficence is defined as “taking action to help others” (American Nurses
Association 2015). When providing education, nurses and providers need to be mindful
to present the information in an open and unbiased way. Although LARC is the most
effective form of contraception for women using opiates, it is ultimately the patient’s
decision to choose the option that is right for them. When providing options counseling,
the nurse or provider should explain the reasoning behind their recommendations, which
is the purpose of the EBP framework. Providers need to utilize their best clinical
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judgement to provide patient education that is based upon the best available research and
focused on the individual values of the patient.
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Table 1
When prescribing opiates to a woman of childbearing age, how likely are you to
provide information about the risks of preconception, antenatal, and postnatal use of
opiates?
Response
Number of Responses
%
Extremely likely

11

37.93%

Somewhat likely

7

24.14%

Neither likely nor unlikely

6

20.69%

Somewhat unlikely

3

10.34%

Extremely unlikely

2

6.90%

Table 2
When prescribing opiates to a woman of childbearing age, how likely are you to
recommend contraception?
Response
Number of Responses
%
Extremely likely

15

51.72%

Somewhat likely

6

20.69%

Neither likely nor unlikely

3

10.34%

Somewhat unlikely

3

10.34%

Extremely unlikely

2

6.90%

19

Table 3
When discussing contraception, how likely are you to recommend long acting
reversible contraception (LARC)?
Response
Number of Responses
%
Extremely likely

23

79.31%

Somewhat likely

3

10.34%

Neither likely nor unlikely

3

10.34%

Somewhat unlikely

0

0%

Extremely unlikely

0

0%

Table 4
When discussing LARC, how likely are you to recommend this method to adolescents
and nulliparous women?
Response
Number of Responses
%
Extremely likely

19

65.52%

Somewhat likely

5

17.24%

Neither likely nor unlikely

5

17.24%

Somewhat unlikely

0

0%

Extremely unlikely

0

0%
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Table 5
Please rate the degree to which you agree or disagree with the following statement:
“Providing patients with educational materials relating to the effects of opiates on
pregnancy and recommending LARC would decrease the number of substance
dependent babies born in Maine”
Response
Number of Responses
%
Strongly agree

12

41.38%

Somewhat agree

10

34.48%

Neither agree nor disagree

4

13.97%

Somewhat disagree

3

10.34%

Strongly disagree

0

0%

Table 6
Please rate the degree to which you agree or disagree with the following
statement: “Providing women with education about the effects of opiates on pregnancy
will influence the patient’s decision to take them.”
Response

Number of Responses

%

Strongly agree

12

41.38%

Somewhat agree

10

34.48%

Neither agree nor disagree

4

13.97%

Somewhat disagree

3

10.34%

Strongly disagree

0

0%
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Table 7
What do you think is the most significant barrier to LARC use?
Response

Number of Responses

%

Provider’s education

2

6.90%

Cost

2

6.90%

Health Care Access
Barriers
Patient understanding of
safety and efficacy

10

34.48%

15

51.72%
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